SECURITIES AND EXCHANGE COMMISSION
                                Washington, D.C.

                                    FORM 8-K


                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                          Date of Report: June 21, 2007
                        (Date of earliest event reported)

                                VASOMEDICAL, INC.
             (Exact name of registrant as specified in its charter)

           Delaware                  0-18105              11-2871434
           --------                  -------              ----------
       (State or other           (Commission File        (IRS Employer
jurisdiction of incorporation)        Number)          Identification No.)


180 Linden Avenue, Westbury, New York                         11590
------------------------------------------            -----------------------
(Address of principal executive offices)                   (Zip Code)



Registrant's telephone number including area code        (516) 997-4600
                                                      ----------------------

          (Former name or former address, if changed since last report)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

[ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act

[ ] Pre-commencement  communications  pursuant to Rule 13e-4c under the Exchange
Act (17 CFR 240.13e-4c)



ITEM 1.01         ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

     On June 21, 2007 we entered into a Securities Purchase Agreement with Kerns
Manufacturing Corp.  ("Kerns").  Concurrently with our entry into the Securities
Purchase Agreement, we also entered into a Distribution Agreement and a Supplier
Agreement  with  Living  Data  Technology  Corporation,  an  affiliate  of Kerns
("Living  Data").  A copy of the  Securities  Purchase  Agreement,  including as
exhibits thereto the Distribution Agreement and Supplier Agreement,  is filed as
Exhibit 1.1 to this report and is  incorporated  in its entirety.  The following
description  of the  terms and  conditions  of each of the  Securities  Purchase
Agreement, the Distribution Agreement and the Supplier Agreement is modified and
supplemented by such reference.

     We sold to Kerns pursuant to the Securities Purchase Agreement,  21,428,572
shares of our common stock at $.07 per share for an aggregate of  $1,500,000  as
well a five-year warrant to purchase  4,285,572 shares of our common stock at an
initial exercise price of $.08 per share (the "Warrant"). We also have an option
to sell an  additional  $1 million of our common stock to Kerns.  The  agreement
further  provided  for  the  appointment  to  our  Board  of  Directors  of  two
representatives  of Kerns.  In  furtherance  thereof,  Mr. Jun Ma and Mr.  Simon
Srybnik,  Chairman of both Kerns and Living Data, have been appointed members of
our Board of Directors.  Pursuant to the Distribution  Agreement, we have become
the  exclusive  distributor  in the United  States of the  AngioNew  ECP systems
manufactured by Living Data. As additional  consideration for such agreement, we
agreed to issue an  additional  6,990,840  shares of our common  stock to Living
Data. Pursuant to the Supplier Agreement,  Living Data now will be the exclusive
supplier to us of the ECP therapy  systems that we market  under the  registered
trademark EECP. The Distribution  Agreement and the Supplier Agreement each have
an initial term extending through May 31, 2012.


     Pursuant to a Registration Rights Agreement, we granted to Kerns and Living
Data, subject to certain restrictions,  "piggyback registration rights" covering
the shares  sold to Kerns as well as the shares  issuable  upon  exercise of the
Warrant and the shares issued to Living Data.


ITEM 3.02         UNREGISTERED SALES OF EQUITY SECURITIES

         See Item 1.01 above.




Item 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL  OFFICERS;  ELECTION OF DIRECTORS;
     APPOINTMENT OF PRINCIPAL  OFFICERS;  COMPENSATORY  ARRANGEMENTS  OF CERTAIN
     OFFICERS

      (d)(1) Mr. Jun Ma and Mr. Simon Srybnik were elected to serve as directors
     on June 21, 2007.

          (2) There are no agreements  related to the appointments  except that:
     (a) the  appointment of Mr. Ma and Mr.  Srybnik  satisfied an obligation of
     Company to appoint two  representatives  of Kerns to the Board of Directors
     under the Securities  Purchase  Agreement,  and (b) the Company's  Board of
     Directors has agreed to use their best efforts to have the  shareholders of
     the Company continue to elect two  representatives of Kerns to the Board of
     Directors. See Item 1.01 above.

          (3) No  determination  of committee  obligations for the Directors has
     been made.

          (4) As  affiliates  of Living Data and Kerns,  Mr. Ma and Mr.  Srybnik
     have each been directly  involved in the  transactions  between Living Data
     and Kerns, and the Company,  which are the Securities  Purchase  Agreement,
     the  Distribution  Agreement and the Supplier  Agreement  described in Item
     1.01 above.

ITEM 9.01         FINANCIAL STATEMENTS AND EXHIBITS

     (c) Exhibits.

          4.1  Securities  Purchase Agreement dated June 21, 2007,  including as
               exhibits  thereto the Supplier  Agreement dated June 21, 2007 and
               the Distribution Agreement dated June 21, 2007.

          4.2  Form of Common Stock Purchase Warrant.

          4.3  Registration Rights Agreement dated June 21, 2007







                                   SIGNATURES



     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                        VASOMEDICAL, INC.
Date: June 25, 2007
                                  By: /s/ John C. K. Hui
                                      ---------------------------------------
                                        John C. K. Hui
                                        President and Chief Executive Officer